Other Species / Isoforms
  DUSP1 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
K57
TIVRRRAKGAMGLEH
1 0
DUSP1 (human) TIVRRRAKGAMGLEH K57
DUSP1 (mouse) TIVRRRAkGAMGLEH K57-ac
K57-ub
TIVRRRAkGAMGLEH
0 1
DUSP1 (human) TIVRRRAkGAMGLEH K57-ub
DUSP1 (mouse) TIVRRRAKGAMGLEH K57
K97-ac
SAALDGAkRDGTLAL
0 1
DUSP1 (human) SAALDGAkRDGTLAL K97-ac
DUSP1 (mouse) SASLDGAKRDGTLAL K97
K97-ub
SAALDGAkRDGTLAL
0 1
DUSP1 (human) SAALDGAkRDGTLAL K97-ub
DUSP1 (mouse) SASLDGAKRDGTLAL K97
K122-ub
AAQVFFLkGGYEAFS
0 2
DUSP1 (human) AAQVFFLkGGYEAFS K122-ub
DUSP1 (mouse) STQVFFLQGGYEAFS Q122
S140-p
PELCSKQstPMGLsL
0 1
DUSP1 (human) PELCSKQstPMGLsL S140-p
DUSP1 (mouse) PELCSKQSTPTGLSL S140
T141-p
ELCSKQstPMGLsLP
0 1
DUSP1 (human) ELCSKQstPMGLsLP T141-p
DUSP1 (mouse) ELCSKQSTPTGLSLP T141
S146-p
QstPMGLsLPLSTSV
0 1
DUSP1 (human) QstPMGLsLPLSTSV S146-p
DUSP1 (mouse) QSTPTGLSLPLSTSV S146
K221-ub
FEGHYQYkSIPVEDN
0 1
DUSP1 (human) FEGHYQYkSIPVEDN K221-ub
DUSP1 (mouse) FEGHYQYKSIPVEDN K221
K230-ub
IPVEDNHkADISSWF
0 2
DUSP1 (human) IPVEDNHkADISSWF K230-ub
DUSP1 (mouse) IPVEDNHKADISSWF K230
K280-ub
LMRTNRVkLDEAFEF
0 7
DUSP1 (human) LMRTNRVkLDEAFEF K280-ub
DUSP1 (mouse) LMRTNRVKLDEAFEF K280
K289-ub
DEAFEFVkQRRSIIs
0 5
DUSP1 (human) DEAFEFVkQRRSIIs K289-ub
DUSP1 (mouse) DEAFEFVKQRRSIIS K289
S296-p
kQRRSIIsPNFSFMG
Upstream
Downstream
1 0
Effects on Modified Protein
  • molecular association, regulation
  • protein degradation
Kinase, in vitro:
  • ERK2 (human)
Putative in vivo kinases:
  • ERK2 (human)
Treatment
  • serum
  • U0126
DUSP1 (human) kQRRSIIsPNFSFMG S296-p
DUSP1 (mouse) KQRRSIISPNFSFMG S296
S323-p
HCSAEAGsPAMAVLD
Upstream
Downstream
1 0
Effects on Modified Protein
  • molecular association, regulation
  • protein degradation
Kinase, in vitro:
  • ERK2 (human)
Putative in vivo kinases:
  • ERK2 (human)
Treatment
  • serum
  • U0126
DUSP1 (human) HCSAEAGsPAMAVLD S323-p
DUSP1 (mouse) HCSAEAGSPAMAVLD S323
S334-p
AVLDRGTsTTTVFNF
Upstream
Downstream
1 0
Effects on Modified Protein
  • phosphorylation
  • protein degradation
  • ubiquitination
Effects on Biological Processes:
  • signaling pathway regulation
Kinase, in vitro:
  • AMPKA2 (human)
Putative in vivo kinases:
  • AMPKA2 (human)
Treatment
  • metformin
  • nicotine
DUSP1 (human) AVLDRGTsTTTVFNF S334-p
DUSP1 (mouse) AVLDRGTSTTTVFNF S334
S359-p
SALSYLQsPITTsPS
Upstream
Downstream
4 0
DUSP1 (human)
S359-p
DUSP1 (mouse)
S359-p
Effects on Modified Protein
  • protein stabilization
Kinase, in vitro:
  • ERK1 (human)
Putative in vivo kinases:
  • ERK1 (human)
Regulatory protein:
  • HSP27 (human)
Treatment
  • estradiol
  • LPS
  • PD98059
  • serum
  • TNF
  • U0126
DUSP1 (human) SALSYLQsPITTsPS S359-p
DUSP1 (mouse) SALNYLKsPITTSPS S359-p
S364-p
LQsPITTsPSC____
Upstream
Downstream
2 0
Effects on Modified Protein
  • protein stabilization
Kinase, in vitro:
  • ERK1 (human)
Putative in vivo kinases:
  • ERK1 (human)
Treatment
  • estradiol
  • LPS
  • PD98059
  • serum
  • U0126
DUSP1 (human) LQsPITTsPSC____ S364-p
DUSP1 (mouse) LKsPITTSPSC____ S364